Policy changes Backwork has recorded, newest first. The most recent change on record is from October 14, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
83,427 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | CGS Administrators | MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis | Codes changed |
| Aug 2, 2026 | CGS Administrators | MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis | New policy |
| Aug 2, 2026 | CGS Administrators | MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma | Codes changed |
| Aug 2, 2026 | CGS Administrators | MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma | New policy |
| Aug 2, 2026 | CGS Administrators | Sacroiliac Joint Injections and Procedures | Codes changed |
| Aug 2, 2026 | CGS Administrators | Sacroiliac Joint Injections and Procedures | New policy |
| Aug 2, 2026 | CGS Administrators | Prostate Cancer Detection with IsoPSA® | Codes changed |
| Aug 2, 2026 | CGS Administrators | Prostate Cancer Detection with IsoPSA® | New policy |
| Aug 2, 2026 | CGS Administrators | MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia | Codes changed |
| Aug 2, 2026 | CGS Administrators | MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia | New policy |
| Aug 2, 2026 | CGS Administrators | MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing | Codes changed |
| Aug 2, 2026 | CGS Administrators | MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing | New policy |
| Aug 2, 2026 | CGS Administrators | Platelet Rich Plasma Injections for Non-Wound Injections | Codes changed |
| Aug 2, 2026 | CGS Administrators | Platelet Rich Plasma Injections for Non-Wound Injections | New policy |
| Aug 2, 2026 | CGS Administrators | MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer | Codes changed |
| Aug 2, 2026 | CGS Administrators | MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer | New policy |
| Aug 2, 2026 | CGS Administrators | Epidural Steroid Injections for Pain Management | Codes changed |
| Aug 2, 2026 | CGS Administrators | Epidural Steroid Injections for Pain Management | New policy |
| Aug 2, 2026 | CGS Administrators | MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer | Codes changed |
| Aug 2, 2026 | CGS Administrators | MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer | New policy |
| Aug 2, 2026 | CGS Administrators | Electroretinography (ERG) | Codes changed |
| Aug 2, 2026 | CGS Administrators | Electroretinography (ERG) | New policy |
| Aug 2, 2026 | CGS Administrators | Off-label Use of Rituximab and Rituximab Biosimilars | Codes changed |
| Aug 2, 2026 | CGS Administrators | Off-label Use of Rituximab and Rituximab Biosimilars | New policy |
| Aug 2, 2026 | CGS Administrators | MolDX: Minimal Residual Disease Testing for Cancer | Codes changed |
| Aug 2, 2026 | CGS Administrators | MolDX: Minimal Residual Disease Testing for Cancer | New policy |
| Aug 2, 2026 | CGS Administrators | Colon Capsule Endoscopy (CCE) | Codes changed |
| Aug 2, 2026 | CGS Administrators | Colon Capsule Endoscopy (CCE) | New policy |
| Aug 2, 2026 | CGS Administrators | Facet Joint Interventions for Pain Management | Codes changed |
| Aug 2, 2026 | CGS Administrators | Facet Joint Interventions for Pain Management | New policy |
| Aug 2, 2026 | CGS Administrators | Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease | Codes changed |
| Aug 2, 2026 | CGS Administrators | Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease | New policy |
| Aug 2, 2026 | CGS Administrators | Computed Tomography Cerebral Perfusion Analysis (CTP) | Codes changed |
| Aug 2, 2026 | CGS Administrators | Computed Tomography Cerebral Perfusion Analysis (CTP) | New policy |
| Aug 2, 2026 | CGS Administrators | Implantable Continuous Glucose Monitors (I-CGM) | Codes changed |
| Aug 2, 2026 | CGS Administrators | Implantable Continuous Glucose Monitors (I-CGM) | New policy |
| Aug 2, 2026 | CGS Administrators | MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer | Codes changed |
| Aug 2, 2026 | CGS Administrators | MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer | New policy |
| Aug 2, 2026 | CGS Administrators | MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells | Codes changed |
| Aug 2, 2026 | CGS Administrators | MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells | New policy |
| Aug 2, 2026 | CGS Administrators | MolDX: Molecular Testing for Solid Organ Allograft Rejection | Codes changed |
| Aug 2, 2026 | CGS Administrators | MolDX: Molecular Testing for Solid Organ Allograft Rejection | New policy |
| Aug 2, 2026 | CGS Administrators | MolDX: Pharmacogenomics Testing | Codes changed |
| Aug 2, 2026 | CGS Administrators | MolDX: Pharmacogenomics Testing | New policy |
| Aug 2, 2026 | CGS Administrators | Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH) | Codes changed |
| Aug 2, 2026 | CGS Administrators | Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH) | New policy |
| Aug 2, 2026 | CGS Administrators | Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea | Codes changed |
| Aug 2, 2026 | CGS Administrators | Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea | New policy |
| Aug 2, 2026 | CGS Administrators | MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease | Codes changed |
| Aug 2, 2026 | CGS Administrators | MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease | New policy |